Study of the pattern of adverse events following immunization of children in a tertiary care hospital

Rekha Y. Aherkar*, Pradeep K. Deshpande, Balasaheb B. Ghongane

Department of Pharmacology, B. J. Government Medical College & Sassoon General Hospital, Pune, Maharashtra, India

Received: 22 April 2016
Accepted: 26 April 2016

*Correspondence to: Dr. Rekha Y. Aherkar, Email: drrekhaaherkar10@gmail.com

ABSTRACT

Background: Success of an immunization programme depends upon awareness regarding usefulness and safety of vaccines. Widespread information on vaccine safety is very essential. Objective of study was to analyze pattern of Adverse Events Following Immunization (AEFI) in children.

Methods: Prospective, observational study was carried out at immunization OPD of B. J. Government Medical College and Sassoon General hospital, Pune, where children receiving routine immunization were analyzed & followed up through telephonic survey of parents. Vaccine Adverse Event Reporting System (VAERS) form was used to record AEFI.

Results: Total 1206 children, aged 0-6 years, received total of 3179 vaccine doses. 22.71% AEFI were reported. Most common AEFI per 1000 doses of all vaccinations was Fever, seen in less than 9 months of age group (84.67%). DPT vaccine was most common vaccine associated with AEFI and maximum (37.8%) adverse events were seen with 1st dose of DPT.

Conclusions: Reporting of AEFI with regular analysis and feedback should be an integral part of immunization programs.

Keywords: Active surveillance, Vaccine safety, Vaccine surveillance, VAERS

INTRODUCTION

The Universal Immunization Programme (UIP) of India is amongst the largest immunization programmes in the world, targeting 27 million infants and 30 million pregnant women. Vaccine pharmacovigilance is the science and activities relating to the detection, assessment, understanding and communication of Adverse Event Following Immunization (AEFI) and other vaccine or immunization-related issues, and to the prevention of untoward effects of the vaccine or immunization. Like other pharmaceutical products, vaccines also carry risk of adverse events. But expectations with regard to vaccine safety are high, as they are administered to healthy individuals. Because of increase in vaccine coverage and additional booster doses, the risk of an adverse event is proportionally increased. Paradoxically, an effective immunization programme will result in decrease in incidence rates of the target diseases, but might also result in an increase in adverse events.

Pharmacovigilance on vaccines in India is still in infantile stage. A strong system for reporting vaccine adverse events (Vaccine Adverse Event Reporting System-VAERS) exists in most developed countries including the US. Though AEFI surveillance in India started along with the UIP in 1985, the AEFI reporting remained suboptimal for long time in the country. A constant flow of complete information on vaccine adverse events is necessary. As only a few Indian studies on adverse events of vaccines could be traced, there is a need of...
pharmacovigilance of vaccines on a large scale in India. The present study aimed to collect data on AEFI and to do active search of adverse events in pediatric population.

**METHODS**

This study was a prospective, observational, single center, six month (15 December 2013 to 15 June 2014) duration. The study protocol was approved by the Institutional Ethics committee. The study was conducted in B. J. Government Medical College and Sassoon general hospital, Pune where total 1206 children aged 0 to 6 years, attending the immunization outpatient department (OPD) were recruited. Children received Oral Polio Vaccine (OPV), Diphtheria-Tetanus- Pertussis (DPT), Hepatitis B, Measles vaccines, and Bacillus Calmette Guerin vaccine (BCG) as per the National Immunization Schedule. To maintain uniformity and identity, DPT was injected in left thigh, Hepatitis B vaccine in right thigh, Measles vaccine in right arm and BCG vaccine in left arm. The study protocol was explained in detail to the parents of children. All the parents willing to participate in the study were asked to fill an informed consent form. A Case Record Form was designed to obtain basic information like demographic data, vaccine details including batch number, manufacturing date, expiry date, manufacturing company etc. (Table 1) Subjects with immune compromised state, allergic reactions, convulsions or other neurological disorder, failure to provide consent were excluded from study. A telephonic survey of parents or guardians was conducted twice, consisting of an initial call on 7th day and a second call on 30th days after the vaccine administration date. The parents of children were questioned about the appearance of any type of reaction that has followed administration of the vaccine. The parents/guardians of children were also given telephone number of the investigator so that they can contact in case of any problem following vaccine administration.

### Table 1: Vaccine details.

| Batch no. | Manufacturing company | Manufacturing date | Expiry date |
|-----------|-----------------------|--------------------|-------------|
| OPV       | Bio-med private limited | 2013 Feb           | 2015 Jan    |
| Q285      | Bio-med private limited | 2013 April         | 2015 March  |
| P210913   | Bio-med private limited | 2013 Sep.          | 2015 Aug    |
| 63AS14013 | Bharat biotech        | 2014 Jan           | 2015 Dec    |
| DPT       | Human biological institute | 2013 June       | 2015 May    |
| 3A2646    | Human biological institute | 2013 May        | 2015 April  |
| TAG05A/13 | Human biological institute | 2013 June       | 2015 May    |
| TAG11B/13 | Human biological institute | 2013 July      | 2015 June   |
| TAG48A/13 | Human biological institute | 2013 Dec       | 2015 Nov    |
| Hepatitis B |                      |                    |             |
| 51AD13020 | Bharat biotech        | 2013 April         | 2016 March  |
| 51AD13027 | Bharat biotech        | 2013 May           | 2016 April  |
| HBV 43/13 | Human biological institute | 2013 Nov       | 2016 Oct    |
| Measles   |                       |                    |             |
| 003F2244  | Serum Institute of India | 2012 Dec       | 2014 Nov    |
| 003F2213A | Serum Institute of India | 2012 Nov      | 2014 Oct    |
| 003N2171A | Serum Institute of India | 2012 Sep     | 2014 Aug    |
| BCG       |                       |                    |             |
| L037      | BCG vaccine laboratory Chennai | 2012 May  | 2014 April |
| GSV-014/13 | Green Signal Bio Pharma Pvt. Ltd. | 2013 Sep | 2015 Aug |

The Vaccine Adverse Events Reporting System Forms (VAERS) form was used to record the adverse events following vaccination. All demographic data, adverse event description and vaccine details including batch number, manufacturer, route, previous doses was entered promptly, in accordance with specific instructions accompanying the VAERS Form. Naranjo Adverse Drug Reaction Probability Scale form (Naranjo score) was used and type of adverse events were divided as definite, probable, possible and doubtful. Children with the complaint of Adverse Event were called back to hospital, examined for AEFI and appropriate treatment was given by pediatrician. Sudden onset adverse events are considered as those which occur within 24 hours of vaccine administration while, delayed adverse events occurred after 24 hours of vaccine administration. The
detailed data was entered into the Microsoft excel sheet and subsequently analyzed statistically by using Microsoft excel 2013.

RESULTS

A total of 1206 children were included in study during 6 month data collection period. Amongst them 610 (50.58%) were male and 596 (49.41%) were female. 0 to 6 year aged children received OPV, DPT, Hepatitis-B, measles and BCG vaccines according to immunization schedule followed in hospital. Total 274 adverse events were reported. Gender distribution of AEFI is shown in Figure 1.

![Figure 1: Gender distribution of adverse events.](image)

As mentioned in Table 2, most of the adverse events were seen in age group of less than 9 months of age (232 out of 274 i.e. 84.67%). In sub group analysis children of 1.5-2.5 month age group had maximum (80) adverse events. Total vaccine doses administered were 3179 (1022 were oral, 2157 were injectable vaccines). Distribution of vaccines is shown in Figure 2. It shows that OPV doses were given to maximum children 1022, followed by Diphtheria-Tetanus- pertussis vaccine doses (978) and Hepatitis-B vaccine doses (766). Total 340 Measles vaccine doses and 73 BCG vaccine doses were administered.

![Figure 2: Distribution of vaccine doses in children.](image)

Table 2: Age wise distribution of adverse events during follow up.

| Age (months) | Number of AEFI on 7th day follow up | Number of AEFI on 30th day follow up | Number of vaccinated children |
|--------------|-------------------------------------|-------------------------------------|-------------------------------|
| 0.01-<1.5   | 19                                  | 0                                   | 53                            |
| 1.5-<2.5    | 77                                  | 3                                   | 244                           |
| 2.5-<3.5    | 62                                  | 2                                   | 193                           |
| 3.5-<9      | 68                                  | 1                                   | 278                           |
| 9-<18       | 11                                  | 1                                   | 193                           |
| 18-<60      | 22                                  | 0                                   | 179                           |
| 60-72       | 8                                   | 0                                   | 66                            |
| Total       | 267                                 | 7                                   | 1206                          |

Table 3: Adverse event pattern per 1000 vaccine doses.

| Name of adverse event | Number of AE reported | Rate per 1000 doses of all vaccinations |
|-----------------------|-----------------------|----------------------------------------|
| Fever                 | 173                   | 54.41                                  |
| Diarrhoea             | 20                    | 6.29                                   |
| Excessive crying      | 8                     | 2.51                                   |
| Running nose          | 1                     | 0.31                                   |
| Injection site reactions |                      |                                        |
| Swelling at injection site | 75                    | 34.77                                  |
| Nodule at injection site | 7                    | 3.24                                   |
| Pain at injection site | 4                     | 1.85                                   |
| Abscess at injection site | 3                    | 1.39                                   |
| Redness at injection site | 1                    | 0.46                                   |
| Total                 | 292                   |                                        |

1Total doses of vaccine administered (n=3179) is the denominator for all except for ‘swelling, redness, nodule, pain at injection site’ and ‘abscess at injection site’ for which only the number of vaccines which were administered by injection (n=2157) is taken as denominator. More than one adverse event was counted separately in this table.
As mentioned in Table 3. Most common AEFI per 1000 doses of all vaccinations was Fever (54.41) followed by swelling at injection site (34.3). Table 4 shows various patterns of adverse events like fever, injection site reactions, diarrhoea and excessive crying etc. Most common adverse event observed was fever, followed by injection site reaction in both male and female (Table 5). Some children had more than one co-existing adverse event, the most frequently occurring of which was the presence of Fever and Swelling at left thigh. Fever with other reaction category constituted fever with any other co-existing adverse event like running nose or pain at injection site or swelling at injection site or excessive crying. Injection site reaction constituted swelling or nodule or abscess or redness or pain at injection site.

### Table 4: Pattern of adverse events and responsible vaccine.

| Type of AEFI               | OPV  | DPT  | Hep-B | Measles | BCG  |
|---------------------------|------|------|-------|---------|------|
| Fever                     | 6+144| 141  | 2+14  | 2+15    |
| Diarrhoea                 | 20   |      |       |         |      |
| Excessive crying          | 7*   | 7*   | 1*    | 1*      |
| Running nose              | 1*   | 1*   |       |         |      |
| **Injection site reactions** |     |      |       |         |      |
| Swelling at injection site| 71   | 4    |       |         |      |
| Nodule at injection site  | 6    | 1    |       |         |      |
| Pain at injection site    | 4    | 1    | 2     |         |      |
| Redness at injection site | 1    |      |       |         |      |
| Abscess at injection site |      |      |       | 3       |      |

*In case of generalized systemic adverse events where more than one vaccine could be responsible for the event, it was difficult to point out single vaccine. So, all vaccines were considered responsible.

### Table 5: Pattern of adverse events among male and female.

| Type of adverse event                  | Male | Female |
|----------------------------------------|------|--------|
| Fever                                  | 89   | 74     |
| Swelling at left thigh                 | 27   | 33     |
| Diarrhoea                              | 12   | 8      |
| Swelling at left thigh and excessive cry| 3    | 0      |
| Fever & Swelling at left thigh         | 2    | 4      |
| Measles vaccine injection site swelling at right arm | 2 | 2 |
| Injection site abscess                 | 2    | 1      |
| Nodule of approximately 2 cm diameter at injection site of DPT | 2 | 1 |
| Nodule of approximately 2-3 cm diameter at injection site of DPT | 1 | 2 |
| Fever & running nose                   | 1    | 0      |
| Fever with excessive crying            | 1    | 0      |
| Fever with pain at injection site      | 1    | 0      |
| Swelling & pain at left thigh, excessive crying | 1 | 0 |
| Excessive crying                       | 1    | 0      |
| Fever with excessive crying, Pain at injection site | 0 | 1 |
| Pain at injection site with excessive crying | 0 | 1 |
| Swelling at left thigh & redness at injection site | 0 | 1 |
| Nodule of approximately 2.5 cm diameter at injection site of measles | 0 | 1 |
| Total                                  | 145  | 129    |

It was observed that maximum (37.8%) adverse events were seen with 1st dose of DPT vaccine & number decreased in subsequent doses (Figure 3). All adverse events were mild to moderate in nature. None of the severe adverse event was observed in this study. Sudden onset events constituted 70.07% (192 out of 274) of total AEFI while 29.93% (82 out of 274) AEFI were Delayed type (Figure 4). Causality assessment as per Naranjo scale showed that 98.18% (269 out of 274) of AEFI were probable and 1.82% (5 out of 274) of AEFI were possible.

![Figure 3: Number of adverse events with DPT vaccine.](image-url)
India has one of the largest Universal Immunization Programs in the world in terms of the number of vaccines used, number of beneficiaries covered and human resources involved. Objectives of AEFI surveillance in country are to monitor immunization safety, detect and respond to adverse events following immunization and also to correct hazardous immunization practices. So the final outcome will lead to reduction of the negative impact of the events on health and improvement of quality of immunization. Vaccine’s post licensure surveillance is an essential part of an immunization program which continuously monitors the safety of routinely used vaccines.10

The present study was performed to assess the pattern of adverse events following OPV, DPT, Hepatitis-B, Measles and BCG vaccines administration. Various studies have been conducted in different countries as a part of their national surveillance programmes.

The methodology of present study was similar to study done by Joshi N et al. 2013 in India11 and Carrasco-Garrido et al. 2004 in Spain12 for 6 months duration. Many other studies related to vaccine adverse events surveillance have used vaccine adverse reporting system data or other vaccine data links. These studies were retrospective unlike present study which is prospective.

The majority of AEFI were from the age group of less than 1 year in the present study. This could be because most of the vaccine doses were administered at this age according to the National Immunization Programme. The incidence of AEFI in present study population is 22.3% which is nearer to a study by Joshi et al. 2013 where incidence was found to be 20.8% and Carrasco-Garrido et al. 2004 in Spain which reported about 19% AEFI.11,12

In current study, the most common adverse event was fever. Zhou et al.13 in US and Joshi et al.11 in India also found fever as most common adverse event. The study by Hu et al.14 in China and Zhang LP et al.15 also stated that most frequently reported AEFI was fever followed by injection site reaction and allergic reaction. A study by Carrasco-Garrido et al.12 in Spain and by Mansoor et al.16 in New Zealand mentioned swelling at the site of injection as the most common AEFI. Vaccines containing aluminium salts as adjuvant, such as diphtheria and tetanus vaccines can cause injection site reactions.17 Improper injection technique may increase the risk of local reactions. Hence, proper vaccination technique and cleaning the injection site reduce further complications.18 DPT was the vaccine showing the highest AEFI and still is the vaccine with the highest occurrence of AEFI in young children.19 DPT vaccine induced injection site swelling may differ according to site of vaccine administration. The incidence of swelling is more when the vaccine is administered on arm than on thigh.20 It was observed that adverse events after first dose of DPT were more and number decreased after subsequent doses.21 The probable mechanisms for development of adverse events may include live viral activity, injection-related direct needle trauma or reactions, immune-mediated reactions and cytokine production.22 One study in Japan quoted diarrhoea as a minor adverse event after oral polio vaccine administration.23

Joshi N et al found AEFI rate 99.2 per 1000 vaccine doses while present study reveals AEFI to be 86.19 per 1000 vaccine doses. The overall average annual reporting rate of AEFI from Zhejiang province in China was 9.2 per 100,000 doses through passive surveillance. This study used National AEFI surveillance system data base and 19 different vaccine’s adverse events in all age groups.14 An overall reporting rate in Australia in 2009 was 11.2 per 100,000 doses in less than 1 year old population and included 33 vaccines in study also through passive surveillance.19 This variation in rates of reported AEFI in different countries could be explained by type of surveillance, type of vaccines under study, variable case definitions, reporting criteria and variable compliance with reporting.

Anaphylactic or acute hypersensitivity reactions may be life-threatening. One must look for such sudden onset reaction and all emergency medicines should be kept ready before hand. Though such anaphylactic reactions were not reported in this study, this possibility should always be kept in mind while administering injectable vaccines. Also equal attention must be paid towards delayed onset reactions as their early detection and prompt treatment may avoid further complications.

The present study has some limitations like study duration is short and follow up is by telephonic calls. The minor ailments may not be reported. This study was performed in tertiary care hospital setup hence outcome of this study may not be applicable to population vaccinated at primary health centers, private hospitals and in camp by non-government organizations. Systemic planned, prospective, large scale study is needed for definitive outcomes.
CONCLUSION

An active search system for adverse events to vaccines is a good method for detecting and quantifying mild adverse events that are usually missed by passive surveillance. However, situations such as under-reporting or difficulty in finding a causal association between the appearance of the adverse events and the administration of the vaccine tend to hamper pharmacovigilance. Vaccines have side-effects, but none of them are as severe as the diseases themselves. The benefits of immunization in preventing disease significantly outweigh the risks of immunization-related adverse events. This study revealed that all adverse events were mild to moderate in nature. Thus after identifying the vaccines responsible for adverse events and the characteristics of the events, one may continue to consider vaccines as safe biological products.

On-going surveillance of AEFI and regular analysis and reporting of these data should be integral in the management of immunization programs. The improved AEFI surveillance and reporting system in India should go in a long way to increase and preserve the faith of the community in the existing and new vaccines and increasing the immunization coverage in India. All AEFI should be noted and reported to Central Drug Standard Control Organization so that database will be generated regarding vaccine use and awareness of vaccine safety.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. National Vaccine Policy, New Delhi, Government of India, Ministry of Health and Family Welfare, 2011. Available at http://mohfw.nic.in/WriteReadData/l892s/1084811197NATIONAL%20VACCINE%20POLICY%20BO_OK.pdf Accessed on 18 Oct 2015.
2. World Health Organization. Causality assessment of adverse event following immunization (AEFI): user manual for the revised WHO classification. 2013. Available at http://apps.who.int/iris/bitstream/10665/80670/1/9789241505338_eng.pdf?ua=1 Accessed on 15 Oct 2015.
3. Waldman EA. Surveillance of adverse effects following vaccination and safety of immunization programs. Rev Saude Publica. 2011;45(1):1-11.
4. Budhiraja S. Pharmacovigilance in vaccine. Indian J Pharmacol. 2010;42(2):116-9.
5. Karande S, Gogtay NJ, Kshirsagar NA. Efficacy and safety of vaccines in Indian children: a review. Paediatric and Perinatal Drug Therapy. 2003;5(3):124-34.
6. Vaccine Adverse Event Reporting System (VAERS): About VAERS program (FAQ). Available at http://vaers.hhs.gov/about/faqs. Accessed on 3 Jan 2014.
7. Chitrakara AJ, Thacker N, Vashishtha VM, Bansal CP, Gupta SG. Adverse Event Following Immunization (AEFI) surveillance in India: position paper of Indian Academy of Pediatrics, 2013. Indian Pediatr. 2013;50:739-41.
8. CDC, Food and Drug Administration. Vaccine Adverse Event Reporting System. VAERS Form. Available at https://vaers.hhs.gov/resources/vaers_form.pdf Accessed on 27 Sep 2015.
9. Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
10. Universal immunization program: Ministry of Health and Family Welfare, Government of India. 2009. Available at http://mohfw.nic.in/WriteReadData/l892s/Immunization_UIP.pdf. Accessed on 17 Sep 2014.
11. Joshi ND, Prajapati HK, Solanki KC, Sukhlecha A, Trivedi HR, Gajera MV, et al. Pattern of adverse events following immunization in an Indian teaching hospital. IJMSPH. 2013;2(1):62-8.
12. Carrasso-Garrido P, Gallardo-Pino C, Jiménez-García R, Tapia MA, de Miguel AG. Incidence of adverse reactions to vaccines in a paediatric population. Clin Drug Invest. 2004;24(8):457-63.
13. Zhou W, Pool V, John K, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS): United States, 1991-2001. MMWR Surveill Summ. 2003;52(1):1-24.
14. Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X, et al. Surveillance for Adverse Events following Immunization from 2008 to 2011 in Zhejiang Province, China. Clin Vacc Immunol. 2013;20(2):211-7.
15. Zhang LP, Yu F, Jin BF, Wang Y, Xu HL, DU Y. Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010. Zhonghua Er Ke Za Zhi. 2012;50(11):859-64.
16. Mansoor O, Pillans PL. Vaccine adverse events reported in New Zealand 1990-5. N Z Med J. 1997;110(1048):270-2.
17. Israeli E. Gulf war syndrome as a part of the autoimmune (auto inflammatory) syndrome induced by adjuvant (ASIA) Lupus. 2012;21(2):190-4.
18. Stephan F, McLisa VD. Vaccine administration: Preventing serious shoulder injuries. J Am Pharm Assoc. 2013;53(2):102-3.
19. Mahajan D, Roomiani I, Gold M, Lawrence G, McIntyre P, Menzies R, et al. Annual report: surveillance of adverse events following immunization in Australia, 2009. Commun Dis Intell. 2010;34(3):259-76.
20. Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL. Vaccination site and risk of local
reactions in children 1 through 6 years of age. Pediatrics. 2013;131(2):283-9.
21. Monteiro SAM, Takano OA, Waldman EA. Evaluation of the Brazilian surveillance system for adverse events following vaccination. Revista Brasileira de Epidemiologia. 2011;14(3):361-71.
22. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J. 2009;28(5):431-32.
23. Sugawara T, Ohkusa Y, Taya K, Yasui Y, Wada N, Sakano M, et al. Diarrhoea as a minor adverse effect due to oral polio vaccine. Jpn J Infect Dis. 2009;62:51-3.

Cite this article as: Aherkar RY, Deshpande PK, Ghongane BB. Study of the pattern of adverse events following immunization of children in a tertiary care hospital. Int J Basic Clin Pharmacol 2016;5:609-15.